The results of multicenter study of efficacy of Helicobacter pylori eradication therapy, conducted according to the recommendations of Maastricht V Consensus Report

Abstract

Objective — to study efficacy and safety of two weeks quadruple therapy with high doses of pantoprazole, bismuth subcitrate, clarithromycin, amoxicillin with concomitant adjuvant symbiotic therapy (Saccharomyces boulardii, Lactobacillus rhamnosus, prebiotic inulin) in the eradication therapy for Helicobacter pylori.Materials and methods. In five centers, thirty patients aged 18 — 65 years with Helicobacter pylori-associated diseases (functional dyspepsia, chronic antral gastritis and peptic duodenal ulcers) were diagnosed and treated. The Helicobacter pylori status was confirmed by rapid urease test, 13С-Urea breath test, enzyme immunoassay with detection of IgG antibodies for Helicobacter pylori. Efficacy of eradication evaluated after four weeks of treatment’s termination with 13С-Urea breath test of Stool Antigen Helicobacter pylori test.Results. Twenty-nine patients completed the treatment protocol in full. H.pylori infection eradication was confirmed in 96.5 % of patients, compliant with the protocol. The mild transitory side effects of therapy were reported in 11 patients (36.6 %), mostly often diarrhea, nausea and black coloring of the feces. Four patients (13 %) reported about appearance of two side effects. The treatment was preliminary terminated in one case because of side effect due to severe nausea on the tenth day of treatment.Conclusions. The studied regimen of quadruple eradication therapy for Helicobacter pylori infection with high doses of pantoprazole, bismuth subcitrate, clarithromycin and amoxicillin with adjuvant treatment by symbiotic Opephera provided eradication of Helicobacter pylori infection in 96.5 % of patients.